Mounjaro Company Stock, Supply Chains and What That Means for You

You've heard stock is patchy, here's what's actually happening

Picture this: you've been approved for Mounjaro, you're ready to start, and someone tells you the company is out of stock. It's a frustrating message, and it's also usually incomplete. Eli Lilly manufactures tirzepatide at a global scale, but distribution into the UK moves through licensed wholesalers before it reaches individual pharmacies. A single pharmacy being unable to fulfil a specific dose pen does not mean the medicine is unavailable across the country, it often means that particular dose, at that particular provider, is on a short lead time.

Demand surged sharply after NICE recommended tirzepatide in December 2024, and Lilly has publicly acknowledged the challenge of scaling supply to meet it. Shortages have been dose-specific: the starter 2.5mg pen has generally remained more available than higher doses, because more patients are at the beginning of their titration journey. If you want a reliable read on current availability, the most useful thing you can do in under a minute is check whether the pharmacy you're considering is listed on the GPhC pharmacy register, a registered pharmacy has the supply relationships and regulatory obligations that unregistered sellers simply do not.

At our pharmacy, we source through Eli Lilly's authorised UK distribution network. When a specific dose is temporarily constrained, our prescribers discuss the clinical options with patients directly rather than dispatching a substitute without explanation.

Why the company behind the medicine matters when you're buying online

Eli Lilly does not sell Mounjaro directly to individuals. The authorised route runs through licensed wholesalers to regulated pharmacies, and from there to patients who hold a valid UK prescription. That structure exists for a reason: every step carries accountability.

The MHRA's enforcement work over the past two years has made clear what happens when that chain is bypassed. In October 2025, officers raided the first illicit UK manufacturing site producing counterfeit tirzepatide pens (in Northampton) and across 2025 as a whole, roughly 20 million doses of illegally traded weight-loss medicines (worth around £45 million) were seized. Fake pens have previously been found to contain entirely different substances, including insulin. The practical implication is straightforward: if a seller can't demonstrate a connection to the licensed supply chain, you have no way of knowing what's actually in the pen.

This is also why asking about where to buy tirzepatide isn't a simple price comparison exercise. The manufacturer's supply chain is a safety guarantee as much as a logistics one. Any offer of Mounjaro without a prescription from a clinical assessment (wherever the seller is based) sits outside that guarantee. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk lets you report suspect sellers, and the regulator actively investigates those reports.

What stock shortages mean for your dose and your titration

Mounjaro's treatment schedule runs from 2.5mg up through 5, 7.5, 10, 12.5 and 15mg, with titration managed by your prescriber in roughly four-week steps. When a specific pen strength is temporarily constrained, the decision about how to handle that (whether to wait, pause, or adjust) belongs with your prescriber, not with a pharmacy acting alone.

This is worth spelling out because some patients, on finding their usual dose unavailable, are tempted to source pens from unverified routes to avoid a break in treatment. The risk of doing so is real and well-documented. A prescription-only medicine supplied without clinical oversight is one where nobody is checking for interactions, contraindications or whether your current dose is still appropriate.

If you're worried about what to do when Mounjaro is out of stock, our clinical team reviews each situation individually. You can also find current availability information through our stock page. The better-stocked providers tend to be those with established wholesaler relationships and the volume to maintain consistent allocations, worth factoring in when you're deciding which provider to use.

For context on what the treatment costs through a regulated private provider, our Mounjaro cost page sets out the price landscape honestly, including what changed when Lilly revised UK list prices in autumn 2025.

The regulated private route when NHS access isn't an option yet

NICE's recommendation for tirzepatide (TA1026) set out a phased NHS rollout that is still in its early cohorts, currently reaching patients with a BMI of 40 or above alongside four or more of the five qualifying conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes). Many people who are clinically suitable don't yet meet those thresholds or would prefer not to wait.

The private route through a regulated online pharmacy fills that gap, provided the pharmacy operates within the licensed supply chain and involves a genuine clinical assessment. At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, the same day) and every repeat order involves clinical re-review before anything is dispatched. Treatment arrives via tracked DPD delivery the next working day, in plain packaging. If you'd like to understand whether you're eligible and what the process involves, you can start a free consultation with our prescribers at any point.